Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01821781 · ClinicalTrials.gov registry record · Phase 2
Immune Disorder HSCT Protocol
A Phase 2 study of Chronic Granulomatous Disease and Severe Combined Immunodeficiency, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01821781 is a Phase 2 study of Chronic Granulomatous Disease and Severe Combined Immunodeficiency that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 31-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01821781, a Phase 2 study of Chronic Granulomatous Disease and Severe Combined Immunodeficiency, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.
Conditions Studied
Interventions
- DRUG Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-04-29 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01821781
The ClinicalTrials.gov registry entry for NCT01821781 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 31-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (35% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Chronic Granulomatous Disease appearing as the primary indexed condition, and to 1 intervention - of which Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan is the first listed.
NCT01821781 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01821781 about?
NCT01821781 is a clinical study titled "Immune Disorder HSCT Protocol". This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce...
What is the current status of trial NCT01821781?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-04-29. Estimated completion is 2026-04.
What conditions does trial NCT01821781 study?
This clinical trial studies the following conditions: Chronic Granulomatous Disease, Severe Combined Immunodeficiency, DiGeorge Syndrome, Wiskott-Aldrich Syndrome, Chediak-Higashi Syndrome.
What interventions are being tested in trial NCT01821781?
The interventions under investigation include: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan (DRUG).
Who is sponsoring clinical trial NCT01821781?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01821781 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Granulomatous Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
COMPLETED · Phase 2
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
RECRUITING · Phase 1
-
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
ACTIVE NOT RECRUITING · Early Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
ACTIVE NOT RECRUITING · NA
-
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Granulomatous Disease
All registered trials for this condition
Severe Combined Immunodeficiency
All registered trials for this condition
Missouri
All trials with a study site in Missouri
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.